LLY logo

Eli Lilly Stock Price

Symbol: NYSE:LLYMarket Cap: US$670.0bCategory: Pharmaceuticals & Biotech

LLY Share Price Performance

US$640.86
-204.45 (-24.19%)
46.1% undervalued intrinsic discount
US$1,190.00
Fair Value
US$640.86
-204.45 (-24.19%)
46.1% undervalued intrinsic discount
US$1,190.00
Fair Value
Price US$640.86
AnalystHighTarget US$1,190.00
AnalystConsensusTarget US$956.67
AnalystLowTarget US$666.27

LLY Community Narratives

AN
AnalystHighTarget
AnalystHighTarget·Updated
Fair Value US$1.19k 46.1% undervalued intrinsic discount

Orforglipron Launch And R&D Will Expand Global Healthcare Access

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget·Updated
Fair Value US$956.67 33.0% undervalued intrinsic discount

Phase III Trials And Manufacturing Will Unlock Future Opportunities

6users have liked this narrative
0users have commented on this narrative
166users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget·Updated
Fair Value US$666.27 3.8% undervalued intrinsic discount

US Manufacturing Investments And Tariff Risks Will Constrain Margins While Pipeline Trials Will Open Prospects

0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative

Recent LLY News & Updates

No updates

Eli Lilly and Company Key Details

US$49.0b

Revenue

US$9.0b

Cost of Revenue

US$40.0b

Gross Profit

US$28.9b

Other Expenses

US$11.1b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 30, 2025
Earnings per share (EPS)
12.37
Gross Margin
81.70%
Net Profit Margin
22.66%
Debt/Equity Ratio
243.6%

Eli Lilly and Company Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About LLY

Founded
1876
Employees
47000
CEO
David Ricks
WebsiteView website
www.lilly.com

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd, as well as Strategic Collaboration with Eli Lilly to advance development of its myeloid engager platform for autoimmune disease. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

U.S. Market Performance

  • 7 Days: 0.2%
  • 3 Months: 12.2%
  • 1 Year: 19.9%
  • Year to Date: 7.6%
In the last week, the market has stayed flat, however the Consumer Staples sector stood out, gaining 3.2%. More promisingly, the market is up 20% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading